Clinical Trial Update: The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 trial update on the efficacy and safety of the fuzuloparib plus bevacizumab combination for recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fuzuloparib

Snippet

Sponsor: Fudan University | Conditions: Recurrent Ovarian Cancer | Phase 2 | Status: UNKNOWN